Core Viewpoint - The company announced that its Executive Director, CEO, and Chairman, Dr. Tian Wenzhi, purchased a total of 50,000 H-shares in the open market at an average price of approximately HKD 7.95 per share, representing about 0.01% of the company's total issued shares [1] Group 1 - Following the purchase, Dr. Tian holds a total of 116 million shares, which accounts for 26.90% of the company's total issued share capital as of the announcement date [1] - Dr. Tian expressed confidence in the overall development prospects and potential growth of the group [1] - Dr. Tian does not rule out the possibility of further increasing his shareholding in the company at an appropriate time, in compliance with applicable laws and regulations [1]

Group 1 - The company announced that Tian Wenzhi purchased a total of 50,000 shares of the company's H-shares on the open market at an average price of approximately 7.9500 HKD per share, representing about 0.01% of the company's total issued shares [1] - Following the purchase, Tian Wenzhi holds a total of 116,084,090 shares, which accounts for 26.90% of the company's total issued share capital as of the date of the announcement [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 ImmuneOnco Biopharmaceuticals (Shanghai) Inc. 宜明昂科生物醫藥技術（上海）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1541） 自願公告 執行董事、首席執行官兼董事會董事長增持股份 本公告由宜明昂科生物醫藥技術（上海）股份有限公司（「本公司」，連同其附屬 公司統稱「本集團」）自願作出，以告知本公司股東及潛在投資者有關本公司執 行董事、首席執行官兼董事會（「董事會」）董事長田文志博士（「田博士」）增持 本公司股份。 董事會獲田博士告知，其已於2025年11月7日於公開市場購買合共50,000股本公 司H股，每股股份平均價格為約7.9500港元，佔本公司已發行股份（「股份」）總 數的約0.01%。緊隨購買後，田博士於合共116,084,090股股份中擁有權益，佔於 本公告日期本公司已發行股本總額的26.90%。 宜明昂科生物醫藥技術（上 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 宜明昂科生物醫藥技術（上海）股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年11月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01541 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 396,277,305 | RMB | | 1 | RMB | | 396,277,305 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 396,277,305 | RMB | | 1 | RM ...

Market Overview - The Hong Kong stock market opened higher on October 24, with the Hang Seng Index rising by 0.81% and the Hang Seng Tech Index increasing by 1.36% [1] - Technology stocks continued their rebound, with Alibaba rising over 2% and launching its first self-developed AI glasses for pre-sale [1] - Semiconductor stocks showed recovery, with Huahong Semiconductor up 2.83% and SMIC up 2.23% [1] - The non-ferrous metals sector also saw a rebound, with Luoyang Molybdenum rising over 4% [1] Individual Stock Movements - Wisco Real Estate resumed trading and surged over 90%, planning to privatize and delist for HKD 1.276 billion [2] Market Sentiment and Predictions - Recent fluctuations in the Hong Kong stock market reflect macroeconomic uncertainties and changing international capital flows, showcasing resilience and structural opportunities [3] - Analysts from Everbright Securities suggest that in the face of external uncertainties, investors may focus on defensive sectors such as Chinese financials, consumer stocks, and high-yield stocks in the short term [3] - The Hang Seng Index's recent low of 25,300 points may serve as a short-term support level, with resistance between 26,000 and 26,300 points [3] - Galaxy Securities notes that the outcome of US-China trade negotiations remains uncertain, which may keep market risk appetite low [3] Investment Strategies - Various institutions recommend a balanced approach to asset allocation, including both risk and safe-haven assets [4][5] - The "barbell strategy" is suggested, combining aggressive investments in technology stocks with stable investments in dividend-paying central enterprise stocks [5] - Focus on sectors benefiting from policy support and low interest rates, such as insurance stocks and essential consumer goods [6][7] Sector Focus - The upcoming Fourth Plenary Session of the 20th Central Committee is expected to enhance market focus on sectors highlighted in the "14th Five-Year Plan" [3][4] - Analysts emphasize the importance of structural themes rather than index levels, particularly in light of the anticipated policies from the Fourth Plenary Session [4] Company News - China Railway Construction signed new contracts totaling CNY 1,518.765 billion in the first three quarters, a year-on-year increase of 3.08% [13] - Zhibo City Technology expects social business revenue of CNY 4.38-4.44 billion for the first nine months, a growth of approximately 34.5%-36.4% [13] - Ping An Good Doctor reported total revenue of CNY 3.725 billion for the first three quarters, a year-on-year increase of 13.6% [13] - Mongolian Energy's total revenue is expected to decrease significantly due to global economic downturns and weak demand in the steel market [13]

Major Events - Minglue Technology (02718) plans to offer 7.219 million Class A shares globally from October 23 to October 28, with cornerstone subscriptions amounting to $59 million [1] - Wisco Properties (00230) received a privatization offer from Wisco Hong Kong at a premium of approximately 104.08%, with trading resuming on October 24 [1] - Junyu Foundation (01757) was acquired by China Venture Capital Holdings for 75% of its shares at a discount of about 79.06%, with trading resuming on October 24 [1] - Kangda Foods (00834) was acquired by Gaosi Shi for approximately 54.69% of the company’s shares at a premium of about 16.23%, with trading resuming on October 24 [1] - Hutchison China MediTech (00013) presented data on HMPL-A251 at the AACR-NCI-EORTC International Conference on Molecular Targeted and Cancer Therapeutics [1] - Giant Bio (02367) received a medical device registration certificate for its Type I α1 collagen lyophilized fiber product [1] - Yiming Anke-B (01541) completed the first patient dosing in the Phase IB/II clinical trial of IMM2510 combined with IMM01 [1] - Heng Rui Medicine (01276) received approval to conduct clinical trials for injection of Rikan Trastuzumab [1] - Hansoh Pharmaceutical (03692) had its application for HS-10365 capsule marketing approval accepted by the National Medical Products Administration [1] - Baixin An-B (02185) completed market access and the first commercial surgery for the IBERIS® RDN system in Switzerland [1] - Haotian International Construction Investment (01341) purchased a total of 646 units of Ethereum as of October 23 [1] Share Buybacks/Reductions - Cornerstone Pharmaceuticals-B (02616) saw CEO Yang Jianxin and senior management purchase an additional 1 million shares [2] - Midea Group (00300) repurchased 1.3434 million A shares for approximately 99.998 million yuan on October 23 [2] - China Communications Construction (01800) repurchased 119.45 million A shares for approximately 10.5994 million yuan on October 23 [2] - Mengniu Dairy (02319) repurchased 700,000 shares for approximately 10.0692 million HKD on October 23 [2] - Lianlian Digital (02598) spent about 7.5555 million HKD to repurchase 967,000 shares on October 23 [2] - Lianyi Rong Technology-W (09959) repurchased 2.47 million shares for approximately 7.4137 million HKD on October 23 [2] - Heng Rui Medicine (01276) repurchased 97,500 A shares for approximately 6.2808 million yuan on October 23 [2] - Gushengtang (02273) repurchased 19,860 shares for approximately 5.8634 million HKD on October 23 [2] Operating Performance - Ping An Good Doctor (01833) reported total revenue of approximately 3.725 billion yuan for the first three quarters, a year-on-year increase of 13.6%, and plans to continue expanding AI technology to enhance medical service efficiency and quality [2] - Sands China Ltd. (01928) reported a 7.5% year-on-year increase in net revenue to $1.9 billion for the third quarter [2] - Livzon Pharmaceutical (01513) announced a net profit attributable to shareholders of 1.754 billion yuan for the first three quarters, a year-on-year increase of 4.86% [2] - China Railway Construction (01186) signed new contracts totaling 1.518765 trillion yuan in the first three quarters, a year-on-year increase of 3.08% [2] - Prada (01913) reported net revenue of 4.07 billion euros for the first three quarters, a year-on-year increase of 9% [2] Additional Performance Metrics - Baio Family Interactive (02100) reported 10.2 million active accounts in the third quarter, a year-on-year increase of 37.8% [3] - Anton Oilfield Services (03337) secured new orders worth 1.273 billion yuan in the third quarter [3]

Company News - China Railway Construction Corporation (01186.HK) reported a total new contract value of 1,518.765 billion yuan for the first three quarters, an increase of 3.08% year-on-year. The new contract value for the third quarter was 462.5954 billion yuan [2] - Zhiyu City Technology (09911.HK) expects total revenue from its social business for the first nine months to be between 4.38 billion and 4.44 billion yuan, representing a year-on-year growth of approximately 34.5% to 36.4%. The innovative business revenue is projected to be between 530 million and 550 million yuan, with a year-on-year growth of about 69.9% to 76.3% [2] - Ping An Good Doctor (01833.HK) reported total revenue of 3.725 billion yuan for the first three quarters, a year-on-year increase of 13.6%, and a net profit of 184 million yuan, up 72.6% year-on-year. The company's F-end and B-end enterprise health business revenue grew by 21.5% year-on-year, serving over 4,500 corporate clients [3] - Livzon Pharmaceutical (01513.HK) reported revenue of 9.116 billion yuan for the first three quarters, an increase of 0.38% year-on-year, and a net profit of 1.754 billion yuan, up 4.86% year-on-year [3] - Mongolian Energy (00276.HK) reported a significant decrease in total revenue for the six months ending September 30, 2025, by no more than 900 million HKD, primarily due to global economic recession and a slowdown in the Chinese steel market [3] - Anning Holdings (00128.HK) issued a profit warning, expecting a profit of approximately 21 million HKD for the first three quarters, a significant turnaround from a loss [3] - Baio Family Interactive (02100.HK) reported 10.2 million active accounts in the third quarter, a quarter-on-quarter increase of 29.1% and a year-on-year increase of 37.8%. The average revenue per paid account was 141.2 yuan, down 19.2% quarter-on-quarter and 13.2% year-on-year [3] - Hengrui Medicine (01276.HK) received approval to conduct clinical trials for its injection of Rukang Qutuzumab, with global sales of similar products totaling approximately 6.557 billion USD [4] - Baixin An-B (02185.HK) completed market access and the first commercial surgery for the IBERIS® RDN system in Switzerland [5] - Hansoh Pharmaceutical (03692) had its application for marketing approval of HS-10365 capsules accepted by the National Medical Products Administration [6] Capital Operations and Buyback Dynamics - Minmetals Land (00230.HK) received a privatization offer from Minmetals Hong Kong, with the offer price representing a premium of 185.71% over the undisturbed closing price [7] - Qizhi Group (00917.HK) received a voluntary lock-up commitment from directors and concert parties, with a lock-up period of 12 months starting from October 23, 2025, involving 103 million shares of the company [7] - Mengniu Dairy (02319.HK) repurchased 700,000 shares at a cost of 10.0692 million HKD, with a repurchase price of 14.33 to 14.4 HKD [7] - Lianlian Digital (02598.HK) repurchased approximately 755.55 million HKD worth of 967,000 shares, with a repurchase price of 7.63 to 7.96 HKD [8]

Group 1 - The company has successfully completed the first patient dosing in the IB/II clinical trial of IMM2510 in combination with IMM01 for the treatment of advanced solid tumors, marking a significant milestone in innovative cancer immunotherapy [1] - IMM2510, developed by the company, is a bispecific molecule targeting VEGF and PD-L1, designed to inhibit angiogenesis, reduce tumor size, and enhance immune response sensitivity [1] - The mechanism of IMM2510 includes blocking the PD-L1/PD-1 interaction and inducing antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP), activating T cells, natural killer cells, and macrophages [1] Group 2 - The company has entered into a licensing and collaboration agreement with Axion Bio, Inc., granting the company commercialization rights for IMM2510 in Greater China while allowing Axion Bio, Inc. exclusive rights for research, development, and commercialization outside Greater China [2] - The company's core product, IMM01, is the first SIRPα-Fc fusion protein to enter clinical stages in China, designed to activate macrophages by blocking the "don't eat me" signal and delivering the "eat me" signal [3] - IMM01 has received orphan drug designation from the FDA for first-line treatment of CMML in combination with azacitidine, demonstrating its potential in the market [3] - The company holds global intellectual property and commercialization rights for IMM01, with a patent family that includes granted patents in China, the US, Japan, and the EU [3]

Group 1 - Company has successfully completed the first patient dosing in the Phase IB/II clinical trial of IMM2510 in combination with IMM01 for the treatment of advanced solid tumors, marking a significant milestone in the field of innovative cancer immunotherapy [1] - IMM2510 (Perivalephap α) is a proprietary dual-specific molecule targeting Vascular Endothelial Growth Factor (VEGF) and Programmed Cell Death Ligand 1 (PD-L1), designed to inhibit angiogenesis, reduce tumor size, and enhance tumor cell sensitivity to immune responses [1] - The mechanism of IMM2510 includes blocking the PD-L1/Programmed Cell Death Protein 1 (PD-1) interaction and inducing Fc-mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP) to activate T cells, natural killer cells, and macrophages [1] Group 2 - The company has entered into a licensing and collaboration agreement with Axion Bio, Inc., granting the company commercialization rights for IMM2510 in Greater China while allowing Axion Bio, Inc. exclusive rights for research, development, and commercialization outside Greater China [2] - The core product IMM01 (Tidapepac) is an innovative molecule targeting CD47, recognized as the first SIRPα-Fc fusion protein to enter clinical stages in China, demonstrating a dual mechanism to activate macrophages [3] - IMM01 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for first-line treatment of Chronic Myelomonocytic Leukemia (CMML) in combination with Azacitidine, showcasing its potential in the market [3] - The company holds global intellectual property and commercialization rights for IMM01, with a patent family that includes granted patents in China, the United States, Japan, and the European Union [3]

Group 1 - Company announced the successful completion of the first patient dosing in the Phase IB/II clinical trial of IMM2510 in combination with IMM01 for the treatment of advanced solid tumors, marking a milestone in innovative cancer immunotherapy [1] - IMM2510 (Pervirafusp alpha) is a dual-specific molecule targeting Vascular Endothelial Growth Factor (VEGF) and Programmed Cell Death Ligand 1 (PD-L1), designed to inhibit angiogenesis, reduce tumor size, and enhance immune response sensitivity [1] - The mechanism of IMM2510 includes blocking the PD-L1/Programmed Cell Death Protein 1 (PD-1) interaction and inducing antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP), activating T cells, natural killer cells, and macrophages [1] Group 2 - The company entered into a licensing and collaboration agreement with Axion Bio, Inc., granting the company commercialization rights for IMM2510 in the Greater China region while allowing Axion Bio, Inc. exclusive rights for research, development, and commercialization outside this region [2] - The core product IMM01 (Tideglusib) is an innovative molecule targeting CD47, being the first SIRPα-Fc fusion protein to enter clinical stages in China, designed to activate macrophages through dual mechanisms [3] - IMM01 has received orphan drug designation from the FDA for first-line treatment of Chronic Myelomonocytic Leukemia (CMML) in combination with Azacitidine, showcasing its potential in the market [3] - The company holds global intellectual property and commercialization rights for IMM01, with a patent family that includes granted patents in China, the United States, Japan, and the European Union [3]